Efficacy of trastuzumab alone therapy was compared to trastuzumab plus taxane therapy in patients of advanced and metastatic breast cancers

Kenichi Sakurai, Katsuhisa Enomoto, Akira Kitajima, Mayumi Tani, Sadao Amano

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)

Abstract

We compared trastuzumab alone therapy (A-group) (n=6) to trastuzumab plus taxane therapy (B-group) (n=12) in patients of advanced and metastatic breast cancers. The response rate of A-group was 33.3%. Six months after, A-group was switched to trastuzumab plus taxane therapy. The response rate of A-group after addition of taxane was improved to 83.3%. The mean duration of response was 6.8 months in A-group after addition of taxane. The response rate of B-group was 83.3%. The mean duration of response was 7.5 months in B-group. The combination therapy of trastuzumab and taxane therapy showed a high response rate. We think that it is possible to start trastuzumab alone therapy because A-group after addition of taxane showed a high response rate. There were no significant differences of immunosuppressive acidic protein (IAP) from the course of chemotherapy in all cases.

Original languageEnglish
Pages (from-to)1911-1913
Number of pages3
JournalJapanese Journal of Cancer and Chemotherapy
Volume34
Issue number12
Publication statusPublished - Nov 2007

Fingerprint

Dive into the research topics of 'Efficacy of trastuzumab alone therapy was compared to trastuzumab plus taxane therapy in patients of advanced and metastatic breast cancers'. Together they form a unique fingerprint.

Cite this